www.bmj.com
Open in
urlscan Pro
104.18.32.115
Public Scan
URL:
https://www.bmj.com/content/371/bmj.m3883/rr
Submission: On September 06 via api from US — Scanned from DE
Submission: On September 06 via api from US — Scanned from DE
Form analysis 2 forms found in the DOM
POST /login
<form action="/login" method="post" id="jnl-bmj-user-login-form" accept-charset="UTF-8">
<div><input type="hidden" name="form_build_id" value="form-arHPplefvzT_wcyKWLpLuynEUNz54TFJIzGg_8a5Mkc">
<input type="hidden" name="form_id" value="jnl_bmj_user_login_form">
<div class="form-type-textfield form-item-name form-item form-group">
<label for="article-p-name">Username <span class="form-required" title="This field is required.">*</span></label>
<input class="form-control form-text required" type="text" id="article-p-name" name="name" value="" size="15" maxlength="60">
</div>
<div class="form-type-password form-item-pass form-item form-group">
<label for="article-p-pass">Password <span class="form-required" title="This field is required.">*</span></label>
<input class="form-control form-text required" type="password" id="article-p-pass" name="pass" size="15" maxlength="128">
</div>
<div class="link">
<div id="edit-forgot" class="form-type-item form-item form-group">
<label for="edit-forgot"><a href="https://www.bmj.com/user/password" title="Retrieve your credentials.">Forgot your log in details?</a> </label>
</div>
</div>
<div class="link">
<div id="edit-activate" class="form-type-item form-item form-group">
<label for="edit-activate"><a href="//journals.bmj.com/cgi/activate/basic">Need to activate</a> </label>
</div>
</div><input class="btn form-submit" type="submit" id="edit-submit--7" name="op" value="Login">
<div id="edit-message" class="form-type-item form-item form-group">
</div>
<hr>
<div id="edit-bma-members" class="form-type-item form-item form-group">
<label for="edit-bma-members"><a href="//bmjverification.bma.org.uk/validate/userdetails?url=https%3A//www.bmj.com/content/371/bmj.m3883/rr%3Fsso%3D" title="Log in here if you are a BMA member.">BMA Member Log In</a> </label>
</div>
<div id="edit-athens" class="form-type-item form-item form-group">
<label
for="edit-athens"><a href="https://openathens-sp.highwire.org/session/init?entityID=https%3A//idp.eduserv.org.uk/openathens&subcode=bmjjournals&hw-shib-return-uri=https%3A//www.bmj.com/accallback/%25253Cfront%25253E">Log in via OpenAthens</a>
</label>
</div>
<div id="edit-shibboleth" class="form-type-item form-item form-group">
<label for="edit-shibboleth"><a href="/login/shibboleth?uri=https%3A%2F%2Fwww.bmj.com%2Faccallback%2F%25253Cfront%25253E&subcode=bmjjournals&env=prod">Log in via your institution</a> </label>
</div>
</div>
</form>POST /content/371/bmj.m3883/rr
<form class="search-form form-search content-search" action="/content/371/bmj.m3883/rr" method="post" id="search-block-form" accept-charset="UTF-8" target="_self">
<div>
<div>
<h2 class="element-invisible">Search form</h2>
<div class="input-group"><input title="Enter the terms you wish to search for." class="container-inline input-append form-control form-text" placeholder="Search The BMJ" type="text" id="edit-search-block-form--2" name="search_block_form"
value="" size="15" maxlength="128"><span class="input-group-btn"><button type="submit" class="btn btn-default">Search</button></span></div><button class="element-invisible btn btn-primary btn btn-primary form-button" type="submit"
id="edit-submit--2" name="op" value="Search">Search</button><input type="hidden" name="form_build_id" value="form-Ze3CO4TmRkU3oXfVs5G9lUdxa9hJAZkwZs_SMKMlpic">
<input type="hidden" name="form_id" value="search_block_form">
<input type="hidden" name="custom_search_paths" value="search/advanced/[key]">
</div>
</div>
</form>Text Content
Skip to main content
Intended for healthcare professionals
* Subscribe
* My Account
* My email alerts
* BMA member login
Login
* Username *
Password *
Forgot your log in details?
Need to activate
--------------------------------------------------------------------------------
BMA Member Log In
Log in via OpenAthens
Log in via your institution
Edition:
International
* US
* UK
* South Asia
Our company
Toggle navigation
The BMJ logo
Site map
Search
SEARCH FORM
Search
Search
* Advanced search
* Search responses
* Search blogs
Toggle top menu
* covid-19
* Research
* At a glance
* Research papers
* Research methods and reporting
* Minerva
* Research news
* Education
* At a glance
* Clinical reviews
* Practice
* Minerva
* Endgames
* State of the art
* What your patient is thinking
* Rapid recommendations
* Student
* News & Views
* At a glance
* News
* Features
* Editorials
* Analysis
* Observations
* Opinion
* Head to head
* Editor's choice
* Letters
* Obituaries
* Views and reviews
* Careers
* Rapid responses
* Campaigns
* At a glance
* Better evidence
* Climate change
* Divestment from fossil fuels
* Patient and public partnership
* Too much medicine
* Wellbeing
* Jobs
* Doctor Jobs UK
* Hospital Jobs UK
* GP Jobs UK
* International Jobs
* Archive
* For authors
* Hosted
1. News & Views
2. The covid-19...
3. How fatal is covid-19 compared with seasonal influenza? The devil is in the
detail.
Rapid response to:
Letters Covid-19: elimination debate
THE COVID-19 ELIMINATION DEBATE NEEDS CORRECT DATA
BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m3883 (Published 06 October 2020)
Cite this as: BMJ 2020;371:m3883
* Article
* Related content
* Article metrics
* Rapid responses
* Response
RAPID RESPONSE:
HOW FATAL IS COVID-19 COMPARED WITH SEASONAL INFLUENZA? THE DEVIL IS IN THE
DETAIL.
Dear Editor
Accurate assessment of the chance of death following exposure to covid-19 is
important, since this statistic has been used by governments to direct lockdowns
in an effort to mitigate these deaths. In correspondence to the BMJ, professors
Baker and Wilson, both proponents of New Zealand’s lockdown, have criticised our
assertion that the infection fatality proportion (IFP) of covid-19 is similar to
seasonal influenza.[1] They claim that the IFP for influenza is 0.039%, about
six times lower than the IFP for covid-19 we cited, a corrected median value of
0.23%.[2]
Clearly, mortality is age-stratified from covid-19. The corrected median
estimates of IFP for people aged lower than 70 years is currently 0.05%, [2]
which, for the population less vulnerable to deaths, is similar to influenza.
However overall estimates for covid-19 are higher, due to the higher fatality
rate in elderly people.
Here, we explore in more detail the assessment of the IFP for the two viruses
and focus on four issues we believe are important:
1. Modelled COVID-19 death has been overestimated
Early in the course of covid-19, the all-age IFP was high, estimated at 0.66%
(credible interval: 0.39 to 1.33%).[3] This led to alarming projections of
covid-19 deaths, if the infection was left to spread. These IFPs were obtained
by adjusting case-fatality proportions by the proportions of returnees testing
positive from repatriation flights from Wuhan. This led to 250,000 deaths
overall being predicted for the UK,[4] justifying lockdowns. Yet observed
fatalities in the UK now show that these models overestimated deaths by seven
times.[5] Similar models in New Zealand predicted 80,000 deaths from the
pandemic if severe lockdowns were not enacted.[6] Barnard et al. estimated
between 12,600 and 33,600 deaths based on a ‘case-fatality ratio’ of 0.75% and
2% respectively— even with lockdowns.[7] We now know that these projections were
too high, and that lockdowns are of questionable value for reducing per capita
mortality.[8]
2. Estimates of IFP
For different diseases, the IFP is estimated in varying ways. For covid-19, it
is the ratio of the cumulative count of clinically assigned covid-19 deaths to
the number of infected people. Frequently, the number of infected people is
estimated by the product of the prevalence of antibody positive cases and the
population count. The prevalence of seropositive subjects is assumed to equate
to a cumulative assessment of viral infections.
Baker and Wilson’s estimate for influenza is derived somewhat differently. The
IFP for influenza is derived from a modelled annual influenza mortality rate,[9]
divided by the influenza seropositive prevalence.[10] This is unlike that for
covid-19. For this disease, deaths have been attributed individually based on
mass testing carried out on an unprecedented scale for any respiratory disease.
While on the face of it this should increase confidence in case numbers, history
suggests this new testing regime, with sharpened focus on covid-19, is likely to
overestimate mortality, as we will discuss.
3. Death ascertainment
New pandemics are often associated with biased changes to cause of death coding.
For example, in the US in 1968-69, where doctors were aware of an impending
influenza A (H3N2) winter, the number of deaths coded as influenza in the summer
of 1968 increased sixteen-fold when compared with the summers in the years
before and after the pandemic.[11] Yet no significant circulation of influenza
was thought to have occurred during that summer. Due to this inaccurate death
certificate recording for influenza, the authors statistically estimated these
deaths, independent of death records, as has the data referred to by Baker and
Wilson.
We see similar evidence for over counting of deaths in countries with high IFPs
for covid-19. A notable example was England where it was impossible to recover
from covid-19 once an individual had tested positive.[12] Reports from Italy
have shown a similar bias in favour of covid-19 death early in that pandemic.
After formal review of apparent covid-19 deaths only 12% of the previous figures
were directly attributable to the new virus.[13]
Evidence for lower mortality comes from countries that have many covid-19 cases
yet few deaths. At the time of writing, Singapore had 57,883 recovered cases and
28 deaths, yielding a case-fatality proportion of 0.05%. We believe, because of
Singapore’s adherence to the case definition when assigning covid-19 deaths,[14]
its numbers more reliably assess mortality, and illuminate the bias present
elsewhere. Further, the denominator is large, likely due to aggressive testing.
If serology were estimated, the IFP of this city state would likely be lower
still.
4. Infection prevalence
As well as bias in the numerator, the denominator in covid-19 IFP calculations
is likely to be lower than true infection counts, because positive antibody
responses wane faster than for influenza.[15 16] This leads to underestimation
of cumulative infection and consequently an overestimation of the IFP.
Supporting evidence comes from levels of positive antibody tests halving after
two months in a cohort of exposed health care workers from Nashville.[17] In
contrast, high levels of influenza antibodies have been documented up to 28
weeks after vaccination in healthy adults in Maryland.[16] Further, evidence of
exposure to covid-19 may be only detectable in specific T-cells (reactive to
spike glycoproteins), rather than in antibodies alone.[18]
Other support for a low IFP for covid-19 come from studies which track serial
antibody tests within individuals. For example, an eightfold increase in
positive antibody prevalence in Tokyo occurred during summer, rising from 5.8%
to 46.8%, yet little increase in fatality from the virus occurred.[19]
So, what is a reasonable IFP for covid-19? The overall corrected median IFP from
61 studies in a meta-analysis is 0.23%.[2] This agrees with a population
serosurvey in Indiana.[20] These studies consider only seropositivity as an
indicator of cumulative exposure to the virus. They have also assumed cause of
death figures are accurate. So, once these factors have been considered, we
believe that our comparison with seasonal influenza is not misleading. Since
models that have incorporated higher IFPs have led to economically crippling
lockdowns,[21] we believe scrutiny of these comparisons are vital and a
reappraisal of the covid-19 IFP is overdue.
Simon Thornley, Section of Epidemiology and Biostatistics, The University of
Auckland
Arthur J. Morris, LabPLUS, Auckland City Hospital
Gerhard Sundborn, Section of Pacific Health, The University of Auckland
Samantha Bailey, Clinical & Pharmaceutical Research Trust, 40 Stewart Street,
Christchurch.
References
1. Baker MG, Wilson N. The covid-19 elimination debate needs correct data. BMJ
2020;371 doi: https://doi.org/10.1136/bmj.m3883
2. Ioannidis J. The infection fatality rate of COVID-19 inferred from
seroprevalence data. Bull World Health Organ 2020
3. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of COVID-19
disease. medRxiv 2020 doi: https://doi.org/10.1101/2020.03.09.20033357
4. Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Impact of non-pharmaceutical
interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. 2020.
DOI 2020;10:77482.
5. National Health Service. COVID-19 Daily Deaths 2020 [Webpage]. Available
from:
https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-da...
accessed 7/11 2020.
6. James A, Hendy SC, Plank MJ, et al. Suppression and mitigation strategies for
control of COVID-19 in New Zealand. medRxiv 2020 doi:
https://doi.org/10.1101/2020.03.26.20044677
7. Telfar Barnard LT, Wilson N, Kvalsig A, et al. Modelled Estimates for the
Spread and Health Impact of Covid-19 in New Zealand: Revised Preliminary Report
for the NZ Ministry of Health. Wellington: University of Otago, 2020.
8. Chaudhry R, Dranitsaris G, Mubashir T, et al. A country level analysis
measuring the impact of government actions, country preparedness and
socioeconomic factors on COVID-19 mortality and related health outcomes.
EClinicalMedicine 2020;25:100464.
9. Khieu TQ, Pierse N, Telfar-Barnard LF, et al. Modelled seasonal influenza
mortality shows marked differences in risk by age, sex, ethnicity and
socioeconomic position in New Zealand. J Infect 2017;75(3):225-33.
10. Huang QS, Bandaranayake D, Wood T, et al. Risk factors and attack rates of
seasonal influenza infection: results of the Southern Hemisphere Influenza and
Vaccine Effectiveness Research and Surveillance (SHIVERS) seroepidemiologic
cohort study. J Infect Dis 2019;219(3):347-57.
11. Thompson WW, Moore MR, Weintraub E, et al. Estimating influenza-associated
deaths in the United States. Am J Public Health 2009;99(S2):S225-S30. doi:
https://doi.org/10.2105/AJPH.2008.151944
12. Loke Y, Heneghan C. Why no-one can ever recover from COVID-19 in England – a
statistical anomaly: Centre for Evidence Based Medicine; 2020 [Webpage].
Available from:
https://www.cebm.net/covid-19/why-no-one-can-ever-recover-from-covid-19-...
accessed 28/10 2020.
13. Newey S. Coronavirus: Is Covid-19 really the cause of all the fatalities in
Italy? Stuff.co.nz: Stuff; 2020 [Webpage]. Available from:
https://www.stuff.co.nz/national/health/coronavirus/120443722/coronaviru...
accessed 29/10 2020.
14. Geddie J, Aravindan A. Why is Singapore's COVID-19 death rate the world's
lowest [Webpage.]. Reuters.com: Thomson Reuters; 2020 [News report]. Available
from:
https://www.reuters.com/article/health-coronavirus-singapore-explainer-i...
accessed 28/10 2020.
15. Weis S, Scherag A, Baier M, et al. Seroprevalence of SARS-CoV-2 antibodies
in an entirely PCR-sampled and quarantined community after a COVID-19
outbreak-the CoNAN study. medRxiv 2020 doi:
https://doi.org/10.1101/2020.07.15.20154112
16. Clements ML, Murphy BR. Development and persistence of local and systemic
antibody responses in adults given live attenuated or inactivated influenza A
virus vaccine. J Clin Microbiol 1986;23(1):66-72.
17. Patel MM, Thornburg NJ, Stubblefield WB, et al. Change in Antibodies to
SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee.
JAMA 2020 doi: https://doi.org/10.1001/jama.2020.18796
18. Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy
donors and patients with COVID-19. Nature 2020:1-5. doi:
https://doi.org/10.1038/s41586-020-2598-9
19. Hibino S, Hayashida K, Ahn AC, et al. Dynamic Change of COVID-19
Seroprevalence among Asymptomatic Population in Tokyo during the Second Wave.
medRxiv 2020:2020.09.21.20198796. doi:
https://doi.org/10.1101/2020.09.21.20198796
20. Blackburn J, Yiannoutsos CT, Carroll AE, et al. Infection fatality ratios
for COVID-19 among noninstitutionalized persons 12 and older: results of a
random-sample prevalence study. Ann Intern Med 2020
21. Joffe A. COVID-19: Rethinking the Lockdown Groupthink. Preprints 2020 doi:
https://doi.org/10.20944/preprints202010.0330.v2
Competing interests: ST and AM have provided paid advice to Auckland
International Airport Ltd related to health risks associated with covid-19.
08 November 2020
Simon Thornley
Senior Lecturer
Arthur J. Morris, Gerhard Sundborn, Samantha Bailey
The University of Auckland
Auckland, New Zealand
simonthornley30
FOLLOW US ON
* Twitter
* Facebook
* YouTube
* RSS
CONTENT LINKS
* Collections
* Health in South Asia
* Women’s, children’s & adolescents’ health
* Zika virus
* Research
* Education
* News and views
* BMJ Opinion
* Rapid responses
* Archive
ABOUT US
* About us
* Editorial staff
* BMJ in the USA
* BMJ in South Asia
* Advisers
* Policies
* Submit your paper
RESOURCES
* Authors
* Reviewers
* BMA members
* Readers
* Subscribers
* Advertisers and sponsors
* Media
* Recruiters
EXPLORE BMJ
* Our company
* BMJ Careers
* BMJ Learning
* BMJ Masterclasses
* BMJ Journals
* BMJ Student
* Academic edition of The BMJ
* BMJ Best Practice
* The BMJ Awards
MY ACCOUNT
* Email alerts
* Activate subscription
INFORMATION
* Contact us
* Complaints
* Cookie settings
* Cookie Policy
* Privacy policy
* Website T&Cs
* Revenue Sources
* HighWire Press
* Sitemap
Copyright © 2023 BMJ Publishing Group Ltd
COOKIES AND PRIVACY
We and our partners store and/or access information on a device, such as unique
IDs in cookies to process personal data. You may accept or manage your choices
by clicking below, including your right to object where legitimate interest is
used, or at any time in the privacy policy page. These choices will be signaled
to our partners and will not affect browsing data.Cookie policy
WE AND OUR PARTNERS PROCESS DATA TO PROVIDE:
Use precise geolocation data. Actively scan device characteristics for
identification. Store and/or access information on a device. Personalised ads
and content, ad and content measurement, audience insights and product
development. List of Partners (vendors)
I Accept Reject All Manage preferences
ABOUT YOUR PRIVACY
* YOUR PRIVACY
* STRICTLY NECESSARY COOKIES
* PERFORMANCE COOKIES
* FUNCTIONAL COOKIES
* TARGETING COOKIES
* STORE AND/OR ACCESS INFORMATION ON A DEVICE
* PERSONALISED ADS AND CONTENT, AD AND CONTENT MEASUREMENT, AUDIENCE INSIGHTS
AND PRODUCT DEVELOPMENT
* USE PRECISE GEOLOCATION DATA
* ACTIVELY SCAN DEVICE CHARACTERISTICS FOR IDENTIFICATION
* ENSURE SECURITY, PREVENT FRAUD, AND DEBUG
* TECHNICALLY DELIVER ADS OR CONTENT
* MATCH AND COMBINE OFFLINE DATA SOURCES
* LINK DIFFERENT DEVICES
* RECEIVE AND USE AUTOMATICALLY-SENT DEVICE CHARACTERISTICS FOR IDENTIFICATION
* GOOGLE & IAB TCF 2 PURPOSES OF PROCESSING
YOUR PRIVACY
We process your data to deliver content or advertisements and measure the
delivery of such content or advertisements to extract insights about our
website. We share this information with our partners on the basis of consent and
legitimate interest. You may exercise your right to consent or object to a
legitimate interest, based on a specific purpose below or at a partner level in
the link under each purpose. These choices will be signaled to our vendors
participating in the Transparency and Consent Framework.
Privacy and cookie policies
List of IAB Vendors
STRICTLY NECESSARY COOKIES
Always Active
These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to
block or alert you about these cookies, but some parts of the site will not then
work. These cookies do not store any personally identifiable information.
Cookies Details
PERFORMANCE COOKIES
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.
Cookies Details
FUNCTIONAL COOKIES
Functional Cookies
These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages. If you do not allow these cookies then
some or all of these services may not function properly.
Cookies Details
TARGETING COOKIES
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.
Cookies Details
STORE AND/OR ACCESS INFORMATION ON A DEVICE
Store and/or access information on a device
Cookies, device identifiers, or other information can be stored or accessed on
your device for the purposes presented to you.
List of IAB Vendors | View Full Legal Text Opens in a new Tab
PERSONALISED ADS AND CONTENT, AD AND CONTENT MEASUREMENT, AUDIENCE INSIGHTS AND
PRODUCT DEVELOPMENT
Personalised ads and content, ad and content measurement, audience insights and
product development
* SELECT BASIC ADS
Switch Label
Ads can be shown to you based on the content you’re viewing, the app you’re
using, your approximate location, or your device type.
Object to Legitimate Interests Remove Objection
* CREATE A PERSONALISED ADS PROFILE
Switch Label
A profile can be built about you and your interests to show you personalised
ads that are relevant to you.
Object to Legitimate Interests Remove Objection
* SELECT PERSONALISED ADS
Switch Label
Personalised ads can be shown to you based on a profile about you.
Object to Legitimate Interests Remove Objection
* CREATE A PERSONALISED CONTENT PROFILE
Switch Label
A profile can be built about you and your interests to show you personalised
content that is relevant to you.
Object to Legitimate Interests Remove Objection
* SELECT PERSONALISED CONTENT
Switch Label
Personalised content can be shown to you based on a profile about you.
Object to Legitimate Interests Remove Objection
* MEASURE AD PERFORMANCE
Switch Label
The performance and effectiveness of ads that you see or interact with can be
measured.
Object to Legitimate Interests Remove Objection
* MEASURE CONTENT PERFORMANCE
Switch Label
The performance and effectiveness of content that you see or interact with
can be measured.
Object to Legitimate Interests Remove Objection
* APPLY MARKET RESEARCH TO GENERATE AUDIENCE INSIGHTS
Switch Label
Market research can be used to learn more about the audiences who visit
sites/apps and view ads.
Object to Legitimate Interests Remove Objection
* DEVELOP AND IMPROVE PRODUCTS
Switch Label
Your data can be used to improve existing systems and software, and to
develop new products
Object to Legitimate Interests Remove Objection
List of IAB Vendors | View Full Legal Text Opens in a new Tab
USE PRECISE GEOLOCATION DATA
Use precise geolocation data
Your precise geolocation data can be used in support of one or more purposes.
This means your location can be accurate to within several meters.
List of IAB Vendors | View Full Legal Text Opens in a new Tab
ACTIVELY SCAN DEVICE CHARACTERISTICS FOR IDENTIFICATION
Actively scan device characteristics for identification
Your device can be identified based on a scan of your device's unique
combination of characteristics.
List of IAB Vendors | View Full Legal Text Opens in a new Tab
ENSURE SECURITY, PREVENT FRAUD, AND DEBUG
Always Active
Your data can be used to monitor for and prevent fraudulent activity, and ensure
systems and processes work properly and securely.
List of IAB Vendors | View Full Legal Text Opens in a new Tab
TECHNICALLY DELIVER ADS OR CONTENT
Always Active
Your device can receive and send information that allows you to see and interact
with ads and content.
List of IAB Vendors | View Full Legal Text Opens in a new Tab
MATCH AND COMBINE OFFLINE DATA SOURCES
Always Active
Data from offline data sources can be combined with your online activity in
support of one or more purposes
List of IAB Vendors | View Full Legal Text Opens in a new Tab
LINK DIFFERENT DEVICES
Always Active
Different devices can be determined as belonging to you or your household in
support of one or more of purposes.
List of IAB Vendors | View Full Legal Text Opens in a new Tab
RECEIVE AND USE AUTOMATICALLY-SENT DEVICE CHARACTERISTICS FOR IDENTIFICATION
Always Active
Your device might be distinguished from other devices based on information it
automatically sends, such as IP address or browser type.
List of IAB Vendors | View Full Legal Text Opens in a new Tab
GOOGLE & IAB TCF 2 PURPOSES OF PROCESSING
Google & IAB TCF 2 Purposes of Processing
Allowing third-party ad tracking and third-party ad serving through Google and
other vendors to occur. Please see more information on Google Ads
https://policies.google.com/privacy?hl=en-US
Cookies Details
Back Button
COOKIE LIST
Filter Button
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Clear
checkbox label label
Apply Cancel
Confirm My Choices
Reject All Allow All